• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Disease Modifying Anti-Rheumatic Drugs
    27 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Salomon, Levin & Elstein Ltd
    partial basket chart

    Folic Acid Analog. Methotrexate 25 mg/ml.
    VIAL (sol. for inj.): 25 mg/ ml X 2 ml, 4 ml,
    8 ml, 20 ml, 40 ml. Dose must be ajust.
    individ. for each pt. accord. to med.
    cond. See lit.
    Antineopl. Chemother.
    Tmt. of gestational choriocarcinoma,
    chorioadenoma destruens and
    hydatidiform mole. Palliation of ALL. Tmt.
    and proph. of menin. leukemia.
    Greatest effect has been observed in
    palliation of acute lymphoblast.(stemcell)
    leukemias in child. In comb. with
    other anticancer agents, may be used for
    the induc. of remis.,but is most common.
    used in the mainten. of induced remis.
    May be used alone, or in comb. with other
    antineoplastic drugs, in the manag. of
    breast canc., epidermoid cancers of the
    head and neck, lung cancer (partic.
    squamous cell ,small cell types), bladder
    cancer and osteogenic cancer. Tmt. of the
    advan.stages (III and IV, Peter’s Staging
    system) of lymphosarcoma, partic. in
    child., and in advanced cases of mycosis
    Psoriasis. Indic. only in the sympt. control
    of sev. recalcitrant, disabling psoriasis
    which is not adeq. responsive to other
    forms of therapy, and only when the diag.
    has been established, as by biopsy and/or
    after dermat. consult. RA:Tmt. of selec.
    adul.with sev. RA, only when the diag. has
    been well established accord. to rheumat.
    standards, with inadeq. response to other
    forms of antirheum. ther., includ. full dose
    NSAIDs and usually a trial of at least one
    or more dis.-modif. antirheum. drugs.
    C/I: Pregnancy, lact., pts. in poor state of
    nutrition, sev. ren. impair. (crCL <20 ml/
    min), sev. liver impair., bone marrow
    hypoplasia, leucopenia,
    thrombocytopenia, anemia, alcohol
    abuse, hypersens. and lung toxic.due to
    methotrexate, serious, acute or chronic
    infect. such as tuberculosis and HIV,
    ulcers of the oral cavity and known
    active GI ulcer dis. Concur. vaccin. with
    live vaccines.

    partial basket chart

    Interleukin-6 Receptor Inhibitor. Tocilizumab 20 mg/ml, 162 mg / 0.9 ml.
    VIALS: 1, 4 x 80 mg/4 ml; 200mg/10 ml;
    400 mg/20 ml.
    RA : 8mg/kg bdy wt. I.V. 1 x every 4
    Pts. bdy wt. > 100 kg, dose exceed. 800
    mg/infus. not recommend. See lit. SJIA:
    <30 kg bdywt: 12 mg/kg bdywt, every
    2 wks; ≥30 kg bdywt: 8 mg/kg bdywt,
    every 2 wks.
    Reduce signs/sympts. in adult pts with
    mod-severe active rheum. arthrit. when
    inad. response to one/more DMARDS or
    TNF antags., or in pts unable to use
    DMARDs. Can be used alone/in comb. with
    methotrexate/other DMARDs. Reduce rate
    progress. joint damage as measured by
    X-ray, improve physic. funct. when in
    combinat. methotrexate. Tmt. active
    system. juv. idiopath. arthrit. in pts. > 2 yrs.
    C/I: Hypersens., active severe infects.

    Actemra 162 mg S.C.
    partial basket chart
    Actemra 162 mg S.C.

    Interleukin-6 Receptor Inhibitor. Tocilizumab 162 mg / 0.9 ml.
    PRE- FILLED SYRINGE.: 4 x 162 mg/0.9 ml
    Inj. S.C. 162 mg once a week.
    In comb. with MTX, for the tmt. of moder.-
    severe active RA in adult pt. who have
    either responded inadequate. to, or who
    were intoler. to, prev. therapy with one or
    more DMARDs or TNF antagonists. In
    these pts., Tocilizumab can be given as
    monother. in case of intolerance to MTX or
    where continued tmt. with MTX is
    C/I: Hypersens., active severe infects.

    Other therapeutic systems under Musculo-Skeletal Disorders